%0 Journal Article
%T Second-line afatinib administration in an elderly patient with squamous cell carcinoma
%A Chrysanthi Sardeli
%A Haidong Huang
%A Melpomeni Toitou
%A Michael Steinheimer
%A Naim Benhassen
%A Nikos Stalikas
%A Paul Zarogoulidis
%A Wolfgang Hohenforst-Schmidt
%J Archive of "Therapeutics and Clinical Risk Management".
%D 2017
%R 10.2147/TCRM.S130816
%X The majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma
%K lung cancer
%K EGFR
%K afatinib
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367451/